Study of drugs Targeting Mitogen-Activated Protein Kinase Pathway in Gastrointestinal Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see if an experimental drug called ERAS-007 is a safe and effective treatment for your cancer when given in combination with other cancer therapies.

What is the Condition Being Studied?

Colorectal Cancer and Pancreatic Cancer

Who Can Participate in the Study?

Adults with colorectal cancer who:
- Have KRAS or NRAS mutations
- Able to swallow oral medication.
- Do not have a history of HIV infection, hepatitis B virus, or hepatitis C virus.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Take the study drug (ERAS-007) in combination with other drugs, which will depend on the type of mutations your cancer has
- Have blood draws
- Give urine samples
- Have regular CT or MRI scans
- Have other tests done during your clinic visits

Study Details

Full Title
[ERAS-007-03] A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00108782
NCT: NCT05039177
Phase
Phase I/II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698